Diasorin Logo

Diasorin

DIA | XMIL

Overview

Corporate Details

ISIN(s):
IT0003492391 (+2 more)
LEI:
8156002878BDF0EE4348
Country:
Italy
Address:
VIA CRESCENTINO, SNC, 13040 SALUGGIA
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

World leaders in the lab diagnostics market, we are specialists in the immunodiagnostics and molecular diagnostics segments and active in the Licensed Technology sector The Company has been developing, producing and marketing reagent kits for laboratory diagnostics all over the world, for over 50 years. Our broad offering of diagnostic tests and Licensed Technology solutions, made available thanks to ongoing investments in research, positions us as the player with the widest range of specialty solutions in the sector and identifies the Group as the "Diagnostics Specialist". Diagnosis is the first step towards understanding a person’s state of health. This is why our tests can make the difference: they are precise and reliable and enable delivery of early diagnosis of various pathologies for millions of people who will then be able to receive the most appropriate therapy.

Social Media

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-07 11:29
Interim Report
Interim Financial Report as at June 30, 2025
English 3.0 MB
2025-08-04 16:51
Report Publication Announcement
Pubblicazione della Relazione finanziaria semestrale al 30 giugno 2025
Italian 184.4 KB
2025-08-04 15:32
Interim Report
Relazione Finanziaria Semestrale del Gruppo Diasorin al 30 giugno 2025
Italian 3.4 MB
2025-07-31 16:24
Investor Presentation
Diasorin H1 2025 Results Presentation
English 1.4 MB
2025-07-31 16:22
Earnings Release
Revenue Growth and Margin Expansion in H1 2025. FY 2025 Guidance Confirmed
English 342.3 KB
2025-07-31 16:21
Earnings Release
Ricavi in crescita ed incremento della marginalità nel 1° semestre 2025. Confer…
Italian 470.4 KB
2025-07-07 09:34
Regulatory News Service
Communication on total amount of voting rights
Italian 210.5 KB
2025-07-07 09:32
Regulatory News Service
Comunicazione dell'ammontare complessivo dei diritti di voto
Italian 232.4 KB
2025-07-01 08:57
Transaction in Own Shares
Diasorin S.p.A. - Allegato 3F
Italian 91.4 KB
2025-05-12 15:37
Post-Annual General Meeting Information
Pubbicazione del verbale dell'Assemblea degli Azionisti del 28 aprile 2025
Italian 184.1 KB
2025-05-12 15:26
Post-Annual General Meeting Information
Verbale Assemblea Ordinaria degli Azionisti 28 aprile 2025
English 21.1 MB
2025-05-06 17:43
Investor Presentation
Diasorin Q1 2025 Results Presentation
English 1.4 MB
2025-05-06 17:39
Earnings Release
Revenue growing +8% and EBITDA margin at 34%: Q1 Results confirm FY 2025 Guidan…
English 369.9 KB
2025-05-06 17:38
Earnings Release
Ricavi in crescita dell’8% ed EBITDA Margin al 34%: i risultati del 1° trimestr…
Italian 417.5 KB
2025-04-29 12:52
Post-Annual General Meeting Information
Shareholders' Meeting April 29, 2025 - Summary report on votes
English 224.5 KB

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Nanobiotix Logo Nanobiotix France NANO
Nanoform Finland OYJ Logo Nanoform Finland OYJ Finland NANOFH
NanoGroup S.A. Logo NanoGroup S.A. Poland NNG
Nattaro Labs AB Logo Nattaro Labs AB Sweden NATTA
Neovacs Logo Neovacs France ALNEV
Newron Pharmaceuticals S.p.A. Logo Newron Pharmaceuticals S.p.A. Italy NWRN
NextCell Pharma AB Logo NextCell Pharma AB Sweden NXTCL
NextFerm Technologies Ltd. Logo NextFerm Technologies Ltd. Israel NXFR
NFL Biosciences Logo NFL Biosciences France ALNFL
Nortem BioGroup Logo Nortem BioGroup Spain MLBIO